Group 1 - The Hong Kong stock market opened lower but rebounded, with the Hang Seng Index rising by 0.56% to close at 20,798.63 points, and the Tech Index increasing by 1.68% to 4,894.48 points [1] - Chip stocks experienced significant gains, with notable increases in individual stocks such as Longi Green Energy rising nearly 23% and Huahong Semiconductor up 19% [1] - Other sectors showed mixed performance, with gold and precious metals rising, automotive stocks recovering, while agricultural stocks continued to decline and duty-free concept stocks lost momentum [1] Group 2 - Individual stock performances included notable gains for companies like Zhongjin Life Science (up nearly 23%), Huahong Semiconductor (up 19%), and Chifeng Jilong Gold (up 13.9%), while companies like Zhaoyan New Drug fell nearly 17% and China Duty Free Group dropped 4.4% [1] - The overall market sentiment reflected a positive trend in the semiconductor sector, indicating potential investment opportunities in this industry [1]

Group 1 - The stock of Changjiang Life Science Technology (00775.HK), owned by Li Ka-shing and Li Zeju, resumed trading today and initially surged over 40% [1] - The stock's gains have since narrowed to below 30% [1]

Group 1 - The company, Changjiang Life Science Technology, has announced promising early results from preclinical laboratory tests of a novel cancer vaccine targeting TROP2, a cell surface glycoprotein overexpressed in various cancers such as breast, lung, pancreatic, and colorectal cancers [1] - TROP2 plays a critical role in cell proliferation, metastasis, and invasion, making it a potential therapeutic target in oncology due to its high expression in cancer cells and minimal presence in normal tissues [1] - The TROP2 cancer vaccine candidate utilizes innovative circular RNA (circRNA) and fusion protein constructs, demonstrating significant tumor growth inhibition in preclinical studies involving over 170 mice, with complete tumor growth suppression observed in all breast cancer studies [1] Group 2 - The incidence of breast cancer, particularly triple-negative breast cancer (TNBC), is rising sharply in Asia, affecting many young women, with higher rates and severity compared to Western countries [2] - The company believes that the TROP2 cancer vaccine shows unprecedented anti-cancer efficacy based on mouse studies and aims to advance it to clinical research stages to provide new treatment options for patients [2] - The company has filed patent applications for the circRNA and fusion protein TROP2 cancer vaccine with the Hong Kong Intellectual Property Department and a provisional patent application with the U.S. Patent and Trademark Office [2] Group 3 - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on April 11, 2025 [3]

Group 1: IF's IPO - IFBH Limited, a leading coconut water brand, has submitted its IPO application to the Hong Kong Stock Exchange, aiming to list on the main board [1] - IF is the second largest coconut water beverage company globally and has held the top position in the coconut water market in mainland China for five consecutive years since 2020, as well as in Hong Kong for nine years since 2016 [1] Group 2: Anta Sports Acquisition - Anta Sports announced a conditional agreement to acquire 100% equity of Callaway Germany Holdco GmbH for a base price of $290 million, plus adjustments for net working capital and other customary items [2] - The acquisition is expected to enhance Anta's international market presence and diversify its product line, with completion anticipated by the end of Q2 or early Q3 2025 [2] Group 3: Sunny Optical's Performance - Sunny Optical reported a 16.3% year-on-year decline in smartphone lens shipments for March 2025, totaling 94.316 million units [3] - In contrast, vehicle lens shipments increased by 16.5% year-on-year, and microscope shipments surged by 78.8% year-on-year, indicating strong growth in these segments [3] Group 4: Changjiang Life Science Suspension - Changjiang Life Science announced a temporary suspension of trading, effective from 9 AM on April 10, with the specific reason yet to be disclosed [4] - The suspension has drawn significant market attention due to the company's influence in the biotechnology sector, with potential implications for market volatility [4] Group 5: BYD Han L Launch - BYD officially launched its flagship sedan, the Han L, with prices starting at 209,800 yuan, offering two major series and various color options [5] - The launch reflects BYD's competitive positioning in the market, and investors are encouraged to monitor sales performance and market feedback [5] Group 6: Hong Kong Stock Market Performance - The Hang Seng Index closed at 20,681.78, with a daily increase of 2.06%, while the Hang Seng Tech Index rose by 2.66% [6]

李嘉诚、李泽钜旗下长江生命科技公布，周四（10日）上午9时正起短暂停止买卖，暂未悉因。 ...

智通财经APP获悉，长江生命科技(00775)绩后跌超6%，截至发稿，跌6.67%，报0.56港元，成交546.21 万港元。 港股异动 | 长江生命科技(00775)绩后跌超6% 年度 股东应占亏损1.27亿港元 同比盈转亏 公告称，业绩于2023年至2024年期间由盈转亏，主要归因于两大因素：公司决意加速科研，投资于科研 的支出由2023年1.46亿港元，上升至2024年2.54亿港元，按年增加1.08亿港元；以及葡萄园投资组合(除 具出售协议之物业外)的公平值取得税后贬值，按年减少4040万港元。 消息面上，3月18日，长江生命科技发布截至2024年12月31日止年度业绩，该集团期内取得收入55.23亿 港元，同比增加3.76%；公司股东应占亏损1.27亿港元，去年同期则公司股东应占溢利1725万港元；每 股基本亏损1.32港仙。 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company reported a loss attributable to shareholders of HKD 126.6 million, a decrease of HKD 143.9 million compared to a profit of HKD 17.3 million in 2023[3] - The group reported revenue of HKD 5,522.7 million for 2024, an increase of 3.8% compared to HKD 5,322.7 million in 2023[26] - The group incurred a net loss of HKD 126.6 million in 2024, compared to a profit of HKD 17.3 million in 2023, representing a significant decline[26] - The company reported a total comprehensive income of HKD 109,154,000 for the year, compared to a loss of HKD 677,705,000 in the previous year[34] - The annual loss for the year was HKD 126,554,000, reflecting a significant improvement from the previous year's losses[34] - The company reported a net loss of HKD 126,554,000 for 2024, compared to a profit of HKD 17,250,000 in 2023[56] Research and Development - Research and development expenditure increased from HKD 145.9 million in 2023 to HKD 254.1 million in 2024, representing an annual increase of HKD 18.2 million[5] - The company's therapeutic cancer vaccine, seviprotimut-L, is currently in the final research phase, undergoing trials as an adjuvant therapy for melanoma patients post-surgery[7] - The company plans to accelerate the development of Halneuron® for pain relief, with a Phase II B clinical trial expected to commence in Q1 2025[6] - The company is strategically investing in liquid biopsy testing projects to provide non-invasive and cost-effective cancer detection solutions[8] - Clinical trial and laboratory expenses rose significantly to HKD 160,811,000, up 59.43% from HKD 100,878,000 in 2023[53] Revenue and Profitability by Segment - The agricultural segment's basic profit contribution was HKD 329.3 million, up 4% from 2023, while including fair value changes, profit decreased by 13% year-on-year[12] - The health products business recorded a profit growth of 3% to HKD 292.5 million compared to 2023, despite inflation and economic instability[10] - The health products business generated revenue of HKD 3,451,588,000, up 6.43% from HKD 3,242,902,000 in 2023[49] Assets and Liabilities - Total assets as of December 31, 2024, were approximately HKD 10,788.6 million, with net assets amounting to HKD 3,511.5 million, equivalent to HKD 0.37 per share[18][32] - The group’s bank borrowings totaled HKD 5,474.9 million as of December 31, 2024, with interest expenses amounting to HKD 310.3 million for the year[18] - The net debt to total equity ratio was approximately 58.36% as of December 31, 2024, indicating a significant leverage position[18] - The company’s total assets were reported at HKD 3,511,548,000 as of December 31, 2024, indicating a strategic focus on asset management[34] Employee and Operational Metrics - The total number of full-time employees increased to 2,033 in 2024, up from 1,932 in 2023, with total employee costs rising by 9.5% to HKD 1,237.6 million[23] - Employee costs totaled HKD 1,237.6 million, an increase of 9.46% from HKD 1,130.4 million in 2023[52] Corporate Governance and Compliance - The company adheres to high standards of corporate governance and has implemented various policies to ensure accountability and transparency[68] - The audit committee reviewed the annual performance for the fiscal year ending December 31, 2024, which was audited by Deloitte[69] - The company has adopted new accounting standards with no significant impact on the financial statements for the current and previous periods[38][41] - The company is currently evaluating the impact of upcoming accounting standards on its financial reporting[47] Dividends and Shareholder Returns - The company declared a final dividend of HKD 0.008 per share, totaling HKD 76,889,000[34] - The company did not recommend a final dividend for the year ending December 31, 2024, consistent with 2023[57] Market and Regional Performance - Revenue for the Asia-Pacific region in 2024 was HKD 2,813,144, a decrease of 0.8% from HKD 2,836,964 in 2023[64] - North America revenue increased by 9.0% to HKD 2,708,189 in 2024 from HKD 2,484,602 in 2023[64] - Non-current assets in the Asia-Pacific region decreased to HKD 4,359,585 in 2024 from HKD 4,968,452 in 2023, a decline of 12.3%[64] - Non-current assets in North America increased slightly to HKD 3,217,387 in 2024 from HKD 3,185,542 in 2023, an increase of 1.0%[64] Strategic Initiatives - The Australian Agribusiness implemented cost-cutting measures and product adjustments to mitigate the impact of material price fluctuations and high market inventory[14] - Vitaquest achieved progress in acquiring new customers and expanding production capacity, enhancing production efficiency through better supplier selection[10] - The group has not engaged in any major acquisitions or disposals during the year[20] - The group’s capital commitments totaled HKD 64.4 million as of December 31, 2024, primarily for machinery and vineyard maintenance[22] - The group conducted scenario analysis to assess risks and opportunities related to climate change, enhancing transparency and risk mitigation strategies[15] Upcoming Events - The annual general meeting for the fiscal year 2025 is scheduled for May 22, 2025[74]

Financial Performance - For the six months ended June 30, 2024, CK Life Sciences reported a profit attributable to shareholders of approximately HKD 1 million, a decrease of 97% compared to HKD 35.9 million in the same period last year[8]. - The company's pre-tax profit, before deducting financial costs, was HKD 174.5 million, largely offset by financial costs of HKD 169.5 million[8]. - The company announced no interim dividend for the year 2024, consistent with 2023[8]. - The health products segment reported a profit of HKD 156.4 million, slightly up from HKD 155 million last year, despite ongoing cost pressures from inflation[15]. - Agricultural-related business profits decreased to HKD 134 million from HKD 159 million last year, impacted by high inventory and a one-time gain from water rights sale last year[16]. - The company reported a significant increase in revenue, achieving a total of $X million for the quarter, representing a Y% growth year-over-year[26]. - The company reported a decrease in operational costs by J%, improving overall profitability[26]. - The profit before tax for the six months ended June 30, 2024, was HKD 4.99 million, a significant decrease of 91.2% from HKD 56.9 million in the prior year[37]. - The net profit for the period was HKD 1.0 million, down 97.3% from HKD 36.9 million in the same period of 2023[40]. - Revenue for the six months ended June 30, 2024, was HKD 2,635.9 million, a slight increase of 2.2% from HKD 2,579.1 million in the same period of 2023[37]. Research and Development - CK Life Sciences is focused on research and development of breakthrough cancer therapies and early cancer detection solutions[10]. - The therapeutic cancer vaccine, seviprotimut-L, is in the final research phase and aims to serve as an effective adjuvant therapy for melanoma patients post-surgery[11]. - The company is expanding its therapeutic cancer vaccine research projects, with promising preclinical results presented at the AACR annual meeting in April, focusing on KRAS and PD-L1[12]. - Halneuron® has received FDA and Health Canada approval for Phase III clinical trials targeting chemotherapy-induced neuropathic pain (CINP), with ongoing Phase IIB trials in South Korea, Canada, and the US[13]. - The company is strategically investing in Pharus, Inc. to develop innovative, non-invasive liquid biopsy tests for early detection of pancreatic and lung cancers[14]. - The company plans to increase investment in research and development, particularly for the third phase of the Polynoma clinical trial, despite rising financial costs[18]. - Research and development expenditures for the period amounted to approximately HKD 72.9 million[34]. Assets and Liabilities - As of June 30, 2024, the group's total assets amounted to approximately HKD 10,888.5 million, including bank deposits and fixed deposits of about HKD 549.2 million[31]. - The group's total liabilities were HKD 6,874.5 million, with bank borrowings of HKD 5,470.0 million primarily used for acquiring overseas businesses and providing general working capital[31]. - The net debt to total equity ratio was approximately 55.07% as of June 30, 2024[31]. - The group's total capital commitments as of June 30, 2024, were HKD 85.4 million, mainly for the purchase of machinery and equipment, and vineyard maintenance[34]. - The total interest expense on bank borrowings for the six months ended June 30, 2024, was HKD 158.7 million[31]. - Current liabilities increased to HKD 2,877.2 million from HKD 2,100.6 million, reflecting a 37% rise[41]. - The total equity as of June 30, 2024, was HKD 4,014.0 million, down from HKD 4,189.3 million at the end of 2023[42]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and has adhered to all relevant codes and best practices[73]. - The company has implemented various governance policies, including anti-fraud and anti-bribery policies, to ensure accountability and transparency[73]. - The company emphasizes the importance of a high-quality board and robust internal controls as part of its governance framework[73]. - The board consists of ten members, including five executive directors, ensuring over one-third are independent non-executive directors as of June 30, 2024[74]. - The audit committee, composed entirely of independent non-executive directors, reviewed the interim report for the six months ending June 30, 2024[78]. - The company has established an internal audit mechanism to continuously assess risk management and internal control systems, focusing on high-risk business activities[77]. - The remuneration committee, primarily composed of independent non-executive directors, is responsible for recommending compensation policies for all directors and senior management[79]. - The nomination committee evaluates the board's structure and diversity, ensuring independent non-executive directors' independence and proposing appointments[80]. Market and Economic Conditions - The global economy is experiencing a slowdown, with trade protectionism, currency fluctuations, and high inflation contributing to uncertainty[83]. - Labor market changes are causing high employee turnover rates, complicating recruitment and training efforts[84]. - Supply chain disruptions are affecting raw material supply and transportation, leading to increased costs and delivery unpredictability[85]. - The company faces intense competition and rapid technological advancements in its operational markets, which may negatively impact its business and financial performance[86]. - The group faces significant risks from industry trends, including high inflation and interest rates, which may adversely affect its business and financial condition[90]. - Financial costs are expected to increase due to high interest rates, impacting the group's financial situation[90]. - The ongoing effects of the COVID-19 pandemic may still impact the group's business and operational performance, depending on various factors including the severity and duration of any future outbreaks[106]. Risks and Challenges - The company must comply with extensive government regulations regarding product development and safety, which can be lengthy and costly[88]. - The success of the company is partly dependent on obtaining and enforcing patent rights, which may face challenges from third parties[89]. - Currency fluctuations may affect the group's financial condition and potential income, as subsidiaries may operate in different currencies[93]. - The group may face challenges in renewing or refinancing bank loans, which could impact liquidity[91]. - Climate change poses risks to the group's assets and operations, affecting product demand, supply, quality, and prices, particularly in agriculture-related sectors[103]. - The group operates in regions prone to natural disasters, which could significantly disrupt operations and adversely affect financial performance[105].

香港交易及結算所有限公司及香港聯合交易所有限公司對本文件的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本文件全 部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (於開曼群島註冊成立之有限公司) (股份代號：0775) 二零二四年中期業績 二零二四年中期業績 截至二零二四年六月三十日止六個月，長江生命科技集團有限公司（「長江生命 科技」或「公司」）錄得未經審核股東應佔溢利約港幣一百萬元，較去年同期下 跌百分之九十七（港幣三千五百九十萬元）。然而，未扣除財務成本之稅前溢利 實為港幣一億七千四百五十萬元，惟當中大部分被港幣一億六千九百五十萬元之 財務成本所抵銷。 董事會宣佈不派發二零二四年度中期股息（二零二三年：無）。 結算日後事項 長江生命科技於結算日後公佈，出售位於澳洲新南威爾士省瑞福利納（Riverina） 地區的 Balranald 葡萄園土地及用水許可證。瑞福利納地區屬內陸葡萄酒產區， 由於葡萄出口下降，當中尤以出口至中國為甚，導致葡萄供應過剩，業務因而受 影響。交易完成後，本公司預期將錄得約八百二十萬澳元（相等於約 港幣四千二百三十萬元）之出售收益。 醫 ...

Financial Performance - For the year ended December 31, 2023, the company recorded a profit attributable to shareholders of HKD 17.3 million, a decrease of 87% compared to HKD 132 million in 2022[5]. - The decline in profit was primarily due to increased financial costs of HKD 159.3 million, which far exceeded the pre-tax profit growth of HKD 23.1 million[5]. - The board of directors does not recommend a final dividend for the year ended December 31, 2023, compared to HKD 0.008 per share in 2022[5]. - The annual profit for 2023 was HKD 17,250, a significant decrease of 87.0% from HKD 131,952 in 2022[106]. - The company's basic earnings per share dropped to 0.18 cents in 2023 from 1.37 cents in 2022, reflecting the decline in profitability[105]. - The financial expenses increased significantly to HKD 322,425 in 2023 from HKD 163,092 in 2022, indicating higher borrowing costs[105]. - The company's profit before tax was HKD 68.6 million, down from HKD 204.9 million in the previous year, indicating a significant decline in profitability[145]. - The company reported a net profit margin of K%, reflecting improved operational efficiencies and cost management strategies[68]. Revenue and Growth - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[60]. - The company's revenue for the year ended December 31, 2023, was HKD 5,322,733, an increase of 0.9% compared to HKD 5,275,590 in 2022[105]. - Revenue from the agriculture-related business decreased to HKD 1,913,356,000 in 2023 from HKD 2,005,001,000 in 2022, a decline of about 4.6%[140]. - Revenue from the human health business increased to HKD 3,242,902,000 in 2023, up from HKD 3,097,090,000 in 2022, reflecting a growth of approximately 4.7%[140]. - The company provided guidance for the next quarter, projecting revenue between $A million and $B million, indicating a growth rate of C%[62]. - New product launches are expected to contribute an additional $D million in revenue, with anticipated market expansion into E regions[63]. Research and Development - The company is focusing on the research and development of breakthrough cancer therapies and early cancer detection solutions, leveraging innovative technology[6]. - The therapeutic cancer vaccine, seviprotimut-L, is in the final research phase and aims to provide effective adjuvant therapy for melanoma patients post-surgery[7]. - The company is actively developing Halneuron® for pain relief in cancer patients, with the second phase B clinical trial ongoing in South Korea and the US[8]. - The company is investing strategically in liquid biopsy diagnostic projects to provide non-invasive and cost-effective cancer detection solutions[9]. - The company plans to initiate the third phase clinical trial for Halneuron® at an appropriate time, prioritizing funding across various research projects[8]. - The company is advancing in the field of therapeutic cancer vaccines and is focused on developing new pain relief products and early cancer detection diagnostics[31]. - The ongoing development of various cancer vaccines targets multiple tumor antigens and immune checkpoint proteins[36]. - The company is also conducting internal research on cancer diagnostics for melanoma and prostate cancer[40]. Operational Efficiency and Cost Management - The company is focusing on internal growth by enhancing operational efficiency and expanding product lines to increase market penetration[52]. - The company aims to improve operational efficiency, targeting a reduction in costs by H% over the next fiscal year[60]. - The company has expanded its production facilities to enhance productivity and product offerings, particularly in its Vitaquest division[10]. - The company is investing in replanting and irrigation optimization to enhance the quality of its vineyard assets[14]. - The company continues to implement measures to identify and manage climate-related risks and opportunities across its supply chain[12]. Assets and Liabilities - The total assets of the company as of December 31, 2023, amounted to HKD 11,247.4 million, with cash and bank deposits of approximately HKD 664.3 million[56]. - The company's total equity as of December 31, 2023, was HKD 4,189.3 million, equivalent to HKD 0.44 per share[56]. - The net debt to total equity ratio was approximately 53.18% as of December 31, 2023[56]. - The company maintained a total bank borrowing of HKD 5,422.9 million, with an interest expense of HKD 300.0 million for the year[56]. - The total carrying value of the group's investment properties as of December 31, 2023, is HKD 1,827,660,000, accounting for approximately 16% of the group's total assets[103]. - The total carrying value of property, plant, and equipment is HKD 3,899,837,000, an increase from HKD 3,663,321,000 as of December 31, 2022, representing a growth of approximately 6.5%[150]. Governance and Management - The board of directors includes key figures such as Li Ka-shing and Li Zeju, who play significant roles in the group's strategic direction[86]. - The management team includes professionals with over 25 years of experience in corporate financial management and business development, indicating strong leadership[67]. - The independent non-executive directors have reviewed the related transactions and confirmed their fairness and reasonableness for the fiscal year 2023[92]. - The company emphasizes sustainable development and governance through its various committees, including the sustainability committee[64]. Sustainability Initiatives - The group is committed to aligning its reporting with the TCFD framework, identifying and prioritizing climate-related risks and opportunities[74]. - The group has installed 1,820 solar panels at the Vitaquest headquarters, generating 401,035 kWh of electricity as of September 2023[74]. - The group has implemented energy audits and carbon reduction plans to achieve net-zero emissions[74]. - Sustainability initiatives are being prioritized, with a commitment to reduce carbon emissions by I% by 2025[61]. Shareholder Information - The company reported a total of 2,838,009,715 shares outstanding, with major shareholders holding significant stakes, including 29.52% by Li Ka-shing Foundation[81]. - Gold Rainbow Int'l Limited holds 4,355,634,570 shares, representing 45.31% of the total shares, indicating strong control over the company[83]. - The total number of shares held by major shareholders reflects a concentrated ownership structure, which may impact governance and decision-making[83]. Financial Reporting and Compliance - The financial statements were audited by Deloitte, who expressed an unmodified opinion on the financial statements[98]. - The group is committed to maintaining transparency and compliance with listing rules regarding related party transactions[87]. - The group has confirmed that all related transactions were conducted on normal commercial terms and in the best interest of the company and its shareholders[91].